参考文献/References:
[1].Xue C,Sowden MP,Berk BC. Extracellular and intracellular cyclophilin A,native and post-translationally modified,show diverse and specific pathological roles in diseases[J]. Arterioscler T hromb V asc B iol,2018,38(5):986-993.
[2].Seizer P,von Ungern-Sternberg SNI,Haug V,et al. Cyclophilin A is a ligand for RAGE in thrombo-inflammation[J]. Cardiovasc Res,2024,120(4):385-402.
[3].Wang C,Jin R,Zhu X,et al. Function of CD147 in atherosclerosis and atherothrombosis[J]. J Cardiovasc T ransl Res,2015,8(1):59-66.
[4].Seizer P,Gawaz M,May AE. Cyclophilin A and EMMPRIN(CD147) in cardiovascular diseases[J]. Cardiovasc Res,2014,102(1):17-23.
[5].Oczypok EA,Perkins TN,Oury TD. All the “RAGE” in lung disease:the receptor for advanced glycation endproducts(RAGE) is a major mediator of pulmonary inflammatory responses[J]. Paediatr Respir R ev,2017,23:40-49.
[6].Kong P,Cui ZY,Huang XF,et al. Inflammation and atherosclerosis:signaling pathways and therapeutic intervention[J]. Signal Transduct Target Ther,2022,7(1):131.
[7].Soehnlein O,Libby P. Targeting inflammation in atherosclerosis—From experimental insights to the clinic[J]. Nat R ev Drug Discov,2021,20(8):589-610.
[8].Abbate A,Toldo S,Marchetti C,et al. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease[J]. Circ R es,2020,126(9):1260-1280.
[9].Zhao X,Zhao X,Di W,et al. Inhibitors of cyclophilin A:current and anticipated pharmaceutical agents for inflammatory diseases and cancers[J]. Molecules,2024,29(6):1235.
[10].Liang L,Lin R,Xie Y,et al. The role of cyclophilins in inflammatory bowel disease and colorectal cancer[J]. Int J Biol Sci,2021,17(10):2548.
[11].Halade GV,Jin YF,Lindsey ML. Matrix metalloproteinase(MMP)-9:a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation[J]. Pharmacol Ther,2013,139(1):32-40.
[12].Khan R,Rheaume E,Tardif JC. Examining the role of and treatment directed at IL-1β in atherosclerosis[J]. Curr A theroscler R ep,2018,20(11):53.
[13].Hettwer J,Hinterdobler J,Miritsch B,et al. Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis[J]. Cardiovasc Res,2022,118(13):2778-2791.
[14].Alfonso A,Bayón J,Gegunde S,et al. High serum cyclophilin C levels as a risk factor marker for coronary artery disease[J]. Sci Rep,2019,9(1):10576.
[15].Huang R,Sun Y,Liu R,et al. ZeXieYin formula alleviates atherosclerosis by inhibiting the MAPK/NF-κB signaling pathway in APOE-/- mice to attenuate vascular inflammation and increase plaque stability[J]. J Ethnopharmacol,2024,327:117969.
[16].Yang W,Bai X,Luan X,et al. Delicate regulation of IL-1β-mediated inflammation by cyclophilin A[J]. Cell Rep,2022,38(11):110513.
[17].Wolf D,Ley K. Immunity and inflammation in atherosclerosis[J]. Circ Res,2019,124(2):315-327.
[18].Gegunde S,Alfonso A,Alvari?o R,et al. Crosstalk between cyclophilins and T lymphocytes in coronary artery disease[J]. Exp Cell Res,2021,400(2):112514.
[19].高海钧,任佳禹,王若琳,等. 内皮细胞损伤及其功能障碍在动脉粥样硬化中作用的研究进展[J/OL].中国全科医学,1-8[2025-03-31]. http://kns.cnki.net/kcms/detail/13.1222.R.20250224.0934.012.html.
[20].Xie Y,Li X,Ge J. Cyclophilin A–FoxO1 signaling pathway in endothelial cell apoptosis[J]. Cell Signal,2019,61:57-65.
[21].刘璐,张文彦,李世英. 亲环素A和白细胞分化抗原147与动脉粥样硬化及缺血性心脑血管病的研究进展[J]. 心脑血管病防治,2021,21(5):488-491.
[22].Olejarz W,?acheta D,Kubiak-Tomaszewska G. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability[J]. Int J Mol S ci,2020,21(11):3946.
[23].Huilcaman R,Venturini W,Fuenzalida L,et al. Platelets,a key cell in inflammation and atherosclerosis progression[J]. Cells,2022,11(6):1014.
[24].Lordan R,Tsoupras A,Zabetakis I. Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis:potential role of antiplatelet agents[J]. Blood Rev,2021,45:100694.
[25].Rath D,von Ungern‐Sternberg S,Heinzmann D,et al. Platelet surface expression of cyclophilin A is associated with increased mortality in patients with symptomatic coronary artery disease[J]. J Thromb Haemost,2020,18(1):234-242.
[26].von Ungern-Sternberg SNI,Vogel S,Walker-Allgaier B,et al. Extracellular cyclophilin A augments platelet-dependent thrombosis and thromboinflammation[J]. Thromb Haemost,2017,117(11):2063-2078.
[27].Wang L,Soe NN,Sowden M,et al. Cyclophilin A is an important mediator of platelet function by regulating integrin αIIbβ3 bidirectional signalling[J]. Thromb Haemost,2014,112(05):873-882.
[28].Seizer P,Sch?nberger T,Sch?tt M,et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP,MMP-9 and M-CSF during foam cell formation[J]. Atherosclerosis,2010,209(1):51-57.
[29].Park JM,Kim A,Oh JH,et al. Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-κB activation[J]. Carcinogenesis,2007,28(4):837-847.
[30].Nigro P,Satoh K,O’Dell MR,et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice[J]. J Exp Med,2011,208(1):53-66.
[31].Yuan W,Ge H,He B. Pro-inflammatory activities induced by CyPA–EMMPRIN interaction in monocytes[J]. Atherosclerosis,2010,213(2): 415-421.
[32].Ramachandran S,Vinitha A,Kartha CC. Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions:a cellular mechanism for accelerated macro vascular disease in diabetes mellitus[J]. Cardiovasc Diabetol,2016, 15(1):152.
[33].Anandan V,Thankayyan Retnabai SK,Jaleel A,et al. Cyclophilin A induces macrophage apoptosis and enhances atherosclerotic lesions in high‐fat diet‐fed hyperglycemic rabbits[J]. FASEB Bioadv,2021,3(5):305-322.
[34].Ravichandran KS,Lorenz U. Engulfment of apoptotic cells:signals for a good meal[J]. Nat Rev Immunol,2007,7(12):964-974.
[35].Kojima Y,Weissman IL,Leeper NJ. The role of efferocytosis in atherosclerosis[J]. Circulation,2017,135(5):476-489.
[36].Anandan V,Thulaseedharan T,Suresh Kumar A,et al. Cyclophilin A impairs efferocytosis and accelerates atherosclerosis by overexpressing CD 47 and down-regulating calreticulin[J]. Cells,2021,10(12):3598.
[37].Lv JJ,Wang H,Zhang C,et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis[J]. Circ Res,2024,134(2):165-185.
[38].Aguilar-Ballester M,Herrero-Cervera A,Vinué ?,et al. Impact of cholesterol metabolism in immune cell function and atherosclerosis[J]. Nutrients,2020,12(7):2021.
[39].方芳. 三七抗动脉粥样硬化药理机制的研究进展[J/OL]. 中华中医药学刊,1-10[2025-03-31]. http://kns.cnki.net/kcms/detail/21.1546.R.20250221.1423.003.html.
[40].Manaswini N,Sreedevi NN,Thummala S,et al. Association of serum cyclophilin A levels with severity of coronary artery disease[J]. J Lab Physicians,2022,14(3):253-259.
[41].严秀红,丁轶,张荣,等. AIS患者血浆亲环素A、可溶性CD147表达与颅内动脉粥样硬化的相关性分析[J]. 脑与神经疾病杂志,2021,29(12):764-768.
[42].Batty M,Bennett MR, Yu E. The role of oxidative stress in atherosclerosis[J]. Cells,2022,11(23):3843.
[43].Li T,Quan H,Zhang H,et al. Silencing cyclophilin A improves insulin secretion,reduces cell apoptosis,and alleviates inflammation as well as oxidant stress in high glucose-induced pancreatic β-cells via MAPK/NF-kb signaling pathway[J]. Bioengineered,2020,11(1):1047-1057.
[44].Xue C,Sowden M,Berk BC. Extracellular cyclophilin A,especially acetylated,causes pulmonary hypertension by stimulating endothelial apoptosis,redox stress,and inflammation[J]. Arterioscler T hromb V asc Biol,2017,37(6):1138-1146.
[45].Cheng F,Yuan W,Cao M,et al. Cyclophilin A protects cardiomyocytes against hypoxia/reoxygenation‐induced apoptosis via the AKT/Nox2 pathway[J]. Oxid Med Cell Longev,2019,2019:2717986.
[46].Cao M,Yuan W,Peng M,et al. Role of CyPA in cardiac hypertrophy and remodeling[J]. Biosci R ep,2019,39(12):BSR20193190.
相似文献/References:
[1]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(9):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[2]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[3]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[4]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(9):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[5]李琦玉 ?张宁 陈婧 黄浙勇.动脉粥样硬化的抗血小板分子靶向治疗[J].心血管病学进展,2019,(5):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
LI Qiyu,ZHANG Ning,CHEN Jing,et al.Anti-Platelet Molecular Targeted Therapy or Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):701.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.010]
[6]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(9):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[7]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[8]徐侨 刘正霞 鲁翔.白介素22在动脉粥样硬化和2型糖尿病中的作用[J].心血管病学进展,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
XU Qiao,LIU Zhengxia,LU Xiang.IL-22 in Atherosclerosis and Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(9):1260.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.019]
[9]石文坚 花蕾 孟祥光 袁义强.环状RNA在冠状动脉粥样硬化性心脏病中的研究进展[J].心血管病学进展,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
SHI Wenjian,HUA Lei,MENG Xiangguang,et al.CircRNA in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2019,(9):1286.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.026]
[10]代承忠 彭礼清 余建群 刘静 蒲华霞.双源CT血管成像评价经导管主动脉瓣置入术术前患者颈动脉斑块[J].心血管病学进展,2019,(8):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]
DAI Chengzhong,PENG Liqing,YU Jianqun,et al.Evaluation of Carotid Arteries Plaques in Patients Referred for TAVI with Dual-source CT Angiography[J].Advances in Cardiovascular Diseases,2019,(9):1182.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.028]